(RTTNews) - Sandoz, Inc., an unit of Novartis Pharma AG, is recalling one lot of deep vein thrombosis (DVT) medication Enoxaparin Sodium in the form of injection for the potential exposure to high ...

Patients exposed to a higher dose may be subject to bleeding complications. Apotex Corp announced the voluntary recall of 2 batches of Enoxaparin Sodium Injection ...

The prophylaxis of thromboembolic disorders (deep vein thrombosis) in patients undergoing: orthopedic surgery of the hip or knee; high-risk abdominal, gynecological, or urological surgeries; ...

July 26, 2010 — The US Food and Drug Administration (FDA) has approved the first generic formulation of enoxaparin sodium injection (Sandoz, Inc; brand name, Lovenox; Sanofi-Aventis US, LLC), a ...

Princeton, NJ, Sandoz Inc. (“Sandoz”) is initiating a recall of one lot (SAB06761A, Exp 04/2023) of Enoxaparin Sodium Injection, USP 40 mg/0.4 mL Single-Dose Syringes to the consumer level. A portion ...

Princeton, New Jersey, April 25, 2012 – Sandoz today announced the introduction of enoxaparin sodium injection, USP 3 mL vials, a generic version of Sanofi's Lovenox® Injection Multiple-Dose Vials, in ...

CHICAGO--(BUSINESS WIRE)--Meitheal Pharmaceuticals, Inc. (“Meitheal”), a fully integrated generic injectables company today announced the launch of Enoxaparin Sodium Injection, USP, the generic ...

The FDA has approved Amphastar Pharmaceuticals' Abbreviated New Drug Application (“ANDA”) for Enoxaparin Sodium Injection 300mg/3mL (100mg/mL) Multiple Dose Vial (MDV). The Company plans to launch ...

The U.S. Food and Drug Administration today approved the first generic version of Lovenox (enoxaparin sodium injection), an anti-coagulant drug used to prevent deep vein thrombosis (DVT), a ...

Silver Spring, MD - The US Food and Drug Administration (FDA) has granted approval of the first generic formulation of enoxaparin (Lovenox, Sanofi-Aventis) sodium injection, a low-molecular-weight ...